Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy

被引:84
作者
Cui, J. Z.
Chiu, A.
Maberley, D.
Ma, P.
Samad, A.
Matsubara, J. A.
机构
[1] Univ British Columbia, Dept Ophthalmol & Visual Sci, Eye Care Ctr, Vancouver, BC V5Z 3N9, Canada
[2] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada
基金
加拿大健康研究院;
关键词
PVR; HGF; CTGF; PDGF;
D O I
10.1038/sj.eye.6702169
中图分类号
R77 [眼科学];
学科分类号
100212 [眼科学];
摘要
Objective: To compare the relative levels of connective tissue growth factor (CTGF), platelet-derived growth factor alpha (PDGF-AA), and hepatocyte growth factor (HGF) in glial and retinal pigment epithelial (RPE) cells of epiretinal membranes from proliferative vitreoretinopathy (PVR). Methods: A total of 37 PVR membranes, of various stages, underwent fluorescent immunohistochemisty and confocal laser scanning microscopy to localize CTGF, HGF, and PDGF-AA in RPE and glial cells. Results: Numerous RPE, and relatively fewer glial cells, were found in all stages of PVR. CTGF immunoreactivity increased from early to late stage PVR and was principally expressed by RPE cells in early stage, and by glial cells in late stage PVR. HGF, expressed by both RPE and glial cells, was principally expressed in mid-stage PVR. PDGF-AA, expressed by both cell types, demonstrated a uniform level of staining throughout all stages of PVR. Conclusions: RPE and glial cells contribute to the expression of CTGF, HGF, and PDGF-AA during PVR, but with specific developmental patterns. PDGF-AA is expressed uniformly throughout all stages of PVR, while HGF expression peaks during mid stage, and CTGF expression is highest during late stage PVR. These results allow for the development of stage-specific therapeutics for PVR that may allow targeting of the early proliferative and/or the late tractional stages of PVR.
引用
收藏
页码:200 / 208
页数:9
相关论文
共 43 条
[1]
Adjuvant 5-FU and heparin prevent PVR [J].
Allinson, RW .
OPHTHALMOLOGY, 2002, 109 (05) :829-830
[2]
Andrews A, 1999, INVEST OPHTH VIS SCI, V40, P2683
[3]
[Anonymous], 1998, Biochim. Biophys. Acta
[4]
RADIATION-THERAPY IN PROLIFERATIVE VITREORETINOPATHY - A PROSPECTIVE RANDOMIZED STUDY [J].
BINDER, S ;
BONNET, M ;
VELIKAY, M ;
GERARD, JP ;
STOLBA, U ;
WEDRICH, A ;
HOHENBERG, H .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1994, 232 (04) :211-214
[5]
Bochaton-Piallat ML, 2000, INVEST OPHTH VIS SCI, V41, P2336
[6]
HEPATOCYTE GROWTH-FACTOR - A MULTIFUNCTIONAL CYTOKINE [J].
BOROS, P ;
MILLER, CM .
LANCET, 1995, 345 (8945) :293-295
[7]
Briggs MC, 2000, INVEST OPHTH VIS SCI, V41, P3085
[9]
Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders [J].
Cassidy, L ;
Barry, P ;
Shaw, C ;
Duffy, J ;
Kennedy, S .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1998, 82 (02) :181-185
[10]
Growth factors in proliferative vitreoretinopathy [J].
Charteris, DG .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1998, 82 (02) :106-106